Astra posts trial win for Ultomiris in IgA nephropathy (AZN)
Summary
AstraZeneca (AZN) stock is in focus as the company plans to seek accelerated approval for Ultomiris in IgA nephropathy after a late-stage trial win. Read more h...
Description
AstraZeneca (AZN) stock is in focus as the company plans to seek accelerated approval for Ultomiris in IgA nephropathy after a late-stage trial win. Read more h...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source